Effects of Low-Dose Interleukin 2 in Advanced Cancer Patients
Author Information
Author(s): R.C. Stein, V. Malkovska, S. Morgan, A. Galazka, C. Aniszewski, S.E. Roy, R.J. Shearer, R.A. Marsden, D. Bevan, E.C. Gordon-Smith, R.C. Coombes
Primary Institution: St George's Hospital Medical School
Hypothesis
Can prolonged low-dose interleukin 2 treatment be clinically effective and non-toxic for patients with advanced cancer?
Conclusion
Low-dose subcutaneous interleukin 2 treatment shows clinical and immunological activity with minor toxicity in patients with advanced cancer.
Supporting Evidence
- Patients treated with 100 mcg daily showed significant immunological effects.
- Two patients with renal cell carcinoma had partial responses lasting 4 and 9 months.
- Low-dose IL2 treatment was well tolerated with minor side effects.
Takeaway
This study tested a medicine called interleukin 2 on cancer patients. It found that a small dose can help fight cancer without making people very sick.
Methodology
Patients received increasing doses of interleukin 2 via self-administered subcutaneous injection for 8 weeks, followed by a 4-week observation period.
Limitations
The study had a small sample size and did not assess lower doses of interleukin 2 for clinical effectiveness.
Participant Demographics
{"age":{"median":60,"range":"40-82"},"sex":{"female":14,"male":21},"previous_treatment":{"0.1-10 mcg group":10,"100 mcg group":2}}
Statistical Information
P-Value
p<0.01
Confidence Interval
{"lymphocyte_count":"0.03-0.65","LAK_cell_activity":"13.7-21.3"}
Statistical Significance
p<0.01
Want to read the original?
Access the complete publication on the publisher's website